Survivin, human recombinant protein
BIRC5; API4; EPR-1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | O15392 |
|---|---|
| Calculated MW | 18.6 kDa |
| Gene ID | 332 |
|---|---|
| Gene Symbol | BIRC5 |
| Other Names | Survivin, BIRC5; API4; EPR-1, Apoptosis inhibitor 4, Apoptosis inhibitor survivin |
| Gene Source | Human |
| Source | E. coli |
| Assay&Purity | SDS-PAGE; ≥90% |
| Assay2&Purity2 | HPLC; |
| Recombinant | Yes |
| Target/Specificity | Survivin |
| Application Notes | Reconstitute to a concentration of 0.1-1.0 mg/ml in PBS. |
| Format | Lyophilized protein |
| Storage | -20°C; Sterile filtered and lyophilized with no additives |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Survivin, a member of the inhibitor of apoptosis (IAP) family, is also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 and in humans is encoded by the BIRC5 gene. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis. Disruption of survivin induction pathways leads to an increase in apoptosis and decrease in tumour growth. Survivin is highly expressed in most human tumours and fetal tissue, but is completely absent in terminally differentiated cells, making survivin an ideal target for studying cancer therapy.
References
Ambrosini G.,et al.Nat. Med. 3:917-921(1997).
Mahotka C.,et al.Cancer Res. 59:6097-6102(1999).
Uren A.G.,et al.Curr. Biol. 10:1319-1328(2000).
Badran A.,et al.Biochem. Biophys. Res. Commun. 314:902-907(2004).
Zheng W.,et al.DNA Seq. 16:321-328(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.

